Valsartan in combination with metformin and gliclazide in diabetic rat model using developed RP-HPLC method

Sampath Kumar Ns,Rasmita Patra,Yedukondalu Kollati,Vijaya R Dirisala

doi:10.1186/s43094-021-00307-2

Abstract

BackgroundOral administration of biguanides (metformin) and sulfonylureas (gliclazide) are the most common approach of management of type 2 diabetes in humans. Among these diabetic patients, approximately 40–60% suffers from hypertension. Hence, the need of the day is application of polytherapy. A major challenge in polytherapy is the drug-drug interactions that may arise. Hence, this study is focused to develop a reverse phase high-performance liquid chromatography (RP-HPLC) method for concurrent estimation of diabetic drug metformin and hypertension drug valsartan using C18 column and find any possible pharmacokinetic interactions between the two drug combinations strategies, i.e., metformin-valsartan and gliclazide-valsartan in streptozotocin-induced diabetic rats.ResultThe bioanalysis of drug-drug interaction pharmacokinetic result showed no significant difference in the tmax of single treatment of gliclazide and single treatment of metformin or upon co-administration with valsartan.ConclusionOur study has shown that polytherapy of valsartan, a drug administered for hypertension along with hypoglycemic drugs metformin and gliclazide, can be advantageous and safe in patients suffering from both diabetes and hypertension.

Highlights

IntroductionOral administration of biguanides (metformin) and sulfonylureas (gliclazide) are the most common approach of management of type 2 diabetes in humans
Oral administration of biguanides and sulfonylureas are the most common approach of management of type 2 diabetes in humans
Concentration; μg.ml−1, microgram per milliliter; %, percentage; SD, standard deviation; % CV, the percentage of coefficient of variation axis which was found to be in the linearity range between 2 and 20 μg.ml−1 for valsartan, whereas the linearity for metformin was observed between 3 to 100 μg.ml−1 for metformin (Fig. 4a, b)

Summary

Introduction

Oral administration of biguanides (metformin) and sulfonylureas (gliclazide) are the most common approach of management of type 2 diabetes in humans Among these diabetic patients, approximately 40–60% suffers from hypertension. Diabetes has become a growing epidemic, and the percentage of patient population is increasing in leaps and bounds [1] It is a chronic condition of metabolic disorder featured by elevated glucose level in blood circulation [2]. The concern among diabetic patients is the multi organ damage that happens in course of the Metformin, the first known line of therapy for type 2 diabetes, acts by reducing the rate of gluconeogenesis and enhances sensitivity of insulin [8], reducing free fatty acids (FFA) through adipose tissue inhibition [9] It showed therapeutic effect on obesity metabolic disorder [10]. Apart from metformin, another drug, i.e., a sulfonylurea, gliclazide is frequently prescribed to control type 2 diabetes

Methods

Results

Discussion

Conclusion